^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Penile Cancer

    Apply
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/13/2019
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    PD-L1 • CD4
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/05/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CD4
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Jingzhuda (entinostat) • PDS01ADC
    Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (NCT04287868)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/09/2020
    Primary completion :
    07/26/2022
    Completion :
    07/01/2026
    PD-L1 • CDKN2A • CD4
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC
    Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/22/2015
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    08/25/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)
    Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (SWOG S1609) (NCT02834013)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/30/2017
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    CD4
    |
    PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088
    A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (NCT05973487)
    Phase 1
    TScan Therapeutics, Inc.
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    05/06/2024
    Primary completion :
    12/30/2026
    Completion :
    12/30/2026
    HLA-A • PRAME • HLA-C
    |
    HLA-A*02
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors (NCT03074513)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    03/03/2017
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    CD4
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types (AcSé) (NCT03012581)
    Phase 2
    UNICANCER
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    06/16/2017
    Primary completion :
    12/22/2022
    Completion :
    11/11/2023
    MSI • POLE
    |
    POLE mutation
    |
    Opdivo (nivolumab)
    HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor (NCT05787535)
    Phase 1
    HRYZ Biotech Co.
    Recruiting
    Last update posted :
    02/02/2024
    Initiation :
    03/21/2023
    Primary completion :
    02/01/2025
    Completion :
    09/01/2025
    HLA-DRB1
    |
    cyclophosphamide • fludarabine IV • HRYZ-T101
    HRYZ-T101 Injection for HPV18 Positive Solid Tumor (NCT05952947)
    Phase 1
    HRYZ Biotech Co.
    Recruiting
    Last update posted :
    02/02/2024
    Initiation :
    11/01/2023
    Primary completion :
    12/01/2027
    Completion :
    02/01/2028
    HLA-DRB1
    |
    cyclophosphamide • fludarabine IV • HRYZ-T101
    HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (20-C-0104) (NCT04432597)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/27/2023
    Initiation :
    08/11/2020
    Primary completion :
    11/22/2022
    Completion :
    11/20/2025
    CD4
    |
    TILs
    |
    bintrafusp alfa (M7824) • PRGN-2009